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        Introduction 
  The Neuregulin1 (Nrg1) gene encodes an extremely important 
and diverse family of proteins that signal by binding to the ErbB 
family of receptor tyrosine kinases. Nrg1-ErbB signaling regu-
lates neural development, glial growth, myelination, and the 
maintenance of synaptic connections in both the peripheral and 
central nervous system (  Michailov et al., 2004  ;   Taveggia et al., 
2005  ;   Chen et al., 2006  ;   Lopez-Bendito et al., 2006  ). Nrg1 acti-
vation of ErbB signaling regulates the levels of several ion 
channels, including subtypes of neuronal nicotinic acetylcho-
line receptors (nAChRs;   Yang et al., 1998  ;   Liu et al., 2001  ; 
  Kawai et al., 2002  ;   Chang and Fischbach, 2006  ),   N -methyl- d -
aspartic acid receptors (  Ozaki et al., 1997  ;   Gu et al., 2005  ), 
   -amino-3-hydroxy-5-methyl-4-isoxazolepropionic  acid  receptors 
(  Kwon et al., 2005  ;   Li et al., 2007  ), and     -amino butyric acid  A  
receptors (  Rieff et al., 1999  ;   Okada and Corfas, 2004  ). Nrg1 has 
been implicated as a schizophrenia susceptibility gene, and the 
potential relationship between Nrg1 and circuits affected in 
schizophrenia underscores the importance of determining the 
molecular mechanisms of action of Nrg1 signaling in the devel-
oping and adult nervous systems (  Stefansson et al., 2002  ). 
  The Nrg1 gene encodes over a dozen different protein 
products. Multiple promoters and alternative splicing leads to 
the synthesis of three (and perhaps as many as six) classes of 
proteins differing in their amino-terminal domains, as well as 
in the EGF-like domain (     or     ), and/or in the length of the 
C termini (  Falls, 2003  ). These differences in primary sequence 
translate into subtle and dramatic differences in signaling strat-
egies. Although Types I and II Nrg1 are either directly secreted 
or released after constitutive cleavage, Type III Nrg1 remains 
membrane tethered as a result of its unique N-terminal trans-
membrane domain (  Wang et al., 2001  ;   Taveggia et al., 2005  ). 
Thus, Types I and II Nrg1 can participate in paracrine signaling, 
whereas Type III Nrg1 predominantly signals in a juxtacrine 
manner. Additionally, it has been shown that Type III Nrg1 also 
functions as a receptor, in that Type III Nrg1  –  ErbB interaction 
results in signaling within the Type III Nrg1  –  expressing cell 
(  Bao et al., 2003, 2004  ). 
  The integrity of a neuron  –  neuron synapse is determined 
by several molecular interactions between pre- and postsynaptic 
cells. Throughout the central and peripheral nervous system, 
T
ype III Neuregulin1 (Nrg1) isoforms are membrane-
tethered proteins capable of participating in bi-
directional juxtacrine signaling. Neuronal nicotinic 
acetylcholine receptors (nAChRs), which can modulate the 
release of a rich array of neurotransmitters, are differen-
tially targeted to presynaptic sites. We demonstrate that 
Type III Nrg1 back signaling regulates the surface expres-
sion of     7 nAChRs along axons of sensory neurons. Stimu-
lation of Type III Nrg1 back signaling induces an increase 
in axonal surface     7 nAChRs, which results from a re  -
dis  tribution of preexisting intracellular pools of     7 rather 
than from increased protein synthesis. We also demonstrate 
that Type III Nrg1 back signaling activates a phosphatidyl-
inositol 3-kinase signaling pathway and that activation 
of this pathway is required for the insertion of preexisting   
  7 nAChRs into the axonal plasma membrane. These ﬁ  nd-
ings, in conjunction with prior results establishing that 
Type III Nrg1 back signaling controls gene transcription, 
demonstrate that Type III Nrg1 back signaling can regulate 
both short-and long-term changes in neuronal function.
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 To label surface   7* nAChRs, primary sensory neurons were 
labeled with     BgTx-488 (Alexa 488  –  conjugated    -bungarotoxin) 
before fi  xation and permeabilization (  Fig. 1 A  ).     -BgTx is an 
effective reagent for probing     7* nAChRs because of its high 
affi  nity for     7* nAChRs (  Ravdin and Berg 1979  ). After fi  x-
ation and permeabilization, we applied antibodies recognizing 
the cysteine-rich domain of Type III Nrg1 (red) or neurofi  lament 
(NF) proteins (blue;   Fig. 1 A  ;   Yang et al., 1998  ). In neurons from 
WT mice, axons were studded with distinct puncta of    BgTx-
488 and Type III Nrg1 along the same sensory axons. Pretreat-
ment with 5   μ  M methyllycaconitine or 1   μ  M of nicotine before 
addition of   BgTx-488 blocked surface labeling of   7* nAChRs, 
confi  rming the specifi  city of surface     BgTx-488 labeling (  Fig. 
1 D  ). We repeated this analysis using sensory neurons isolated 
from Type III Nrg1 
   /     embryos. Labeling with    BgTx-488 
identifi  ed discrete clusters of     7* nAChRs on the axonal surface 
of mutant neurons (  Fig. 1 A  ). However, when we quantifi  ed the 
number of these     BgTx-488 clusters we found that the mutants 
had     50% fewer clusters than WT neurons (WT, 6.47   ±   0.69 
clusters/100   μ  m; Type III Nrg1 
   /    , 3.22   ±   0.59 clusters/100   μ  m; 
  Fig. 1 B  ). Additionally, we found that the mutants had a 35% re-
duction in mean cluster area relative to WT neurons (WT, 0.26   ±   
0.02   μ  m 
2  ; Type III Nrg1 
   /    , 0.17   ±   0.02   μ  m 
2  ;   Fig. 1 C  ). 
  Although there is a difference in     7* nAChR clusters 
expressed along axons of Type III Nrg1 
   /     sensory neurons, we 
did not detect an overall reduction of total     7 protein in mutant 
neurons (  Fig. 1 E  ). This result, coupled with our fi  ndings in 
 Fig.  1  (A – C) ,  indicates that Type III Nrg1 specifi  cally affects 
the surface expression of     7* nAChRs. The decrease in surface 
    7* nAChRs along axons of Type III Nrg1 
   /     neurons did not 
result from general defi  cits in endocytic recycling because these 
neurons retained WT rates of transferrin receptor recycling (Fig. 
S1, A and B, available at http://www.jcb.org/cgi/content/full/
jcb.200710037/DC1). We next looked to see whether Type III 
Nrg1 
   /     neurons have defects in axonal targeting of presynaptic 
proteins. We did not detect differences in the axonal targeting of 
synaptophysin or vesicular glutamate transporter 1 (vGlut1) 
along mutant axons (Fig. S1, C and D). 
  To demonstrate that the     BgTx-488 surface binding mea-
surements refl  ected the presence of functional     7* nAChRs, we 
quantifi  ed internal concentrations of Ca 
2+   along sensory axons 
after a 1-min application of 1   μ  M of nicotine. In response to 
nicotine, we detected an increase in internal concentrations of 
Ca 
2+   within 1 min along axons of WT neurons (  Fig. 1, F and G  ). 
When this experiment was repeated in the presence of 1   μ  M 
    BgTx, we did not detect an increase in intracellular concentra-
tions of Ca 
2+  , indicating that the nicotine-induced changes were 
mediated by functional     7* nAChRs. Nicotine application did 
not increase internal Ca 
2+   concentrations in Type III Nrg1 
   /    
axons (  Fig. 1 G  ), a result which is consistent with a signifi  cant 
decrease in surface     7* nAChRs in these neurons. 
  Type III Nrg1 back signaling increases 
surface expression of     7* nAChR clusters 
  Type III Nrg1 functions as a membrane-tethered bidirectional 
signaling molecule (  Bao et al., 2003, 2004  ). To test the possibil-
ity that Type III Nrg1, acting as a receptor, contributes to the 
nAChRs function as cation-selective ligand-gated ion channels 
and play important roles in synaptic signaling (  Berg and Conroy, 
2002  ). There is increasing evidence for the importance of 
nAChRs in the modulation of transmitter release from pre-
synaptic terminals (  McGehee et al., 1995  ;   MacDermott et al., 
1999  ), neuronal survival (  Dajas-Bailador et al., 2000  ;   Mechawar 
et al., 2004  ), and postsynaptic signaling (  Zhang et al., 1996  ; 
  Zhang and Berg, 2007  ). Individual nAChR channels have unique 
biological functions that are determined by the pentameric 
combination of 11 distinct subunits:    2 –   7,    9,     10, and    2 –   4 
(  Rosenberg et al., 2002  ). Of particular interest are the    7* 
nAChRs (    7-containing nAChRs) because of their high perme-
ability to calcium and abundant expression in both mammalian 
and avian peripheral nervous systems (  Roth and Berg, 2003  ; 
  Fucile et al., 2005  ). 
  The Type III isoform of Nrg1 was identifi  ed as the nerve-
derived factor responsible for increasing acetylcholine-evoked 
currents in neurons and was shown to regulate expression of 
neuronal nAChR subunit mRNAs, including that of    7  ( Yang 
et al., 1998  ). More recent fi  ndings in our laboratory reveal a 
requirement for presynaptic Type III Nrg1 in potentiation of 
glutamatergic transmission by nicotine in a central sensory 
motor  –  gating circuit (Du, C., C. Zhong, M. Hancock, D.A. 
Talmage, and L.W. Role. 2004. Society for Neuroscience 34th 
Annual Meeting; unpublished data). These results inspired us to 
investigate the molecular mechanisms underlying presynaptic 
Type III Nrg1  ’  s cell-autonomous effect on functional    7* 
nAChRs along axonal projections. 
  In this paper, we show that presynaptic Type III Nrg1 is 
required for normal levels of presynaptically targeted    7* 
nAChRs in primary sensory neurons. Sensory neurons from 
Type III Nrg1 mutant mice exhibit defi  cits of the surface expres-
sion of     7* nAChRs. Acute stimulation of Type III Nrg1 back 
signaling increases the number of     7* nAChRs on sensory 
axons from wild-type (WT), but not from homozygous Type III 
Nrg1, mutant embryos. These increases in axonal surface    7* 
nAChRs result from redistribution of preexisting intracellular 
pools of     7 rather than from increased     7 protein synthesis. 
Increases in surface pools of     7* nAChR are accomplished, 
at least in part, by local activation of a phosphatidylinositol 
3-kinase (PtdIns 3K) signaling pathway, which in turn stimu-
lates the membrane insertion of intracellular    7*  nAChRs. 
  Results 
  Reduction of Type III Nrg1 expression 
results in decreased axonal     7 nAChR 
surface expression 
  Subsets of primary sensory neurons within the dorsal root gan-
glia (DRG) express Type III Nrg1 and    7  nAChR  subunit 
mRNAs ( Boyd et al., 1991 ;  Wolpowitz et al., 2000 ;  Genzen et al., 
2001  ;   Taveggia et al., 2005  ). In the following experiments, we 
examined the expression of     7* nAChRs and Type III Nrg1 on 
the surface of axons from sensory neurons of WT or Type III 
Nrg1 
   /     mouse embryos. Embryonic neurons were used for 
these experiments because mutant mice lacking Type III Nrg1 
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with the maximal response occurring after 6 h (  Fig. 2 C  ) and 
sustained for 24 h (  Figs. 1 B, 2 B, and 3 A  ). Many of the sur-
face     7* nAChR clusters induced by B4-ECD treatment were 
localized in close proximity to membrane-bound B4-ECD 
( Fig.  2  D ). 
  Prior studies have shown that activation of ErbB tyro-
sine kinase signaling can alter the surface expression of    7* 
nAChRs in neurons (  Liu et al., 2001  ;   Kawai et al., 2002  ; 
  Chang and Fischbach, 2006  ). To verify that the increase in 
surface clusters we detected in response to B4-ECD treatment 
was mediated by Type III Nrg1 acting as a receptor, we as-
sessed the response of sensory neurons treated with B4-ECD 
in the presence of 2   μ  M ErbB inh. (inhibitors of ErbB tyrosine 
kinase activity; PD 168393 and PD 158780) for 1 h (  Fig. 2 E  ). 
We also assessed the effect on     7* nAChRs of acute activation 
of ErbB signaling by treating neurons with recombinant Nrg1   
peptide (Nrg1-ECD, 10 ng/ml). In response to B4-ECD treat-
ment, we detected an increase in surface     7* nAChR clusters 
along axons in the presence of ErbB inh. (ErbB inh., 12.31   ±   
2.43 clusters/100-  μ  m axonal length; and ErbB inh. + B4-ECD, 
20.94   ±   2.37 clusters/100-  μ  m axonal length;   Fig. 2 E  ). Con-
versely, we did not detect an increase in axonal surface    7* 
nAChR clusters in response to Nrg1-ECD treatment (B2-ECD 
[control], 11.30   ±   1.74 clusters/100-  μ  m axonal length; and 
Nrg1-ECD, 13.20   ±   2.72 clusters/100-  μ  m axonal length;   Fig. 2 E  ). 
regulation of     7* nAChR levels on sensory axons, we treated 
WT or Type III Nrg1 
   /     sensory neurons with 2 nM of either the 
extracellular domain (ECD) of ErbB2 (B2-ECD; control) or 
ErbB4 (B4-ECD) for 24 h (  Fig. 2, A and B  ). B4-ECD, but not 
B2-ECD, binds with high affi  nity to the EGF-like domain of 
Nrg1 (Fig. S2 A, available at http://www.jcb.org/cgi/content/full/
jcb.200710037/DC1;   Fitzpatrick et al., 1998  ;   Bao et al., 2003  ). 
We visualized     7* nAChRs present on the surface of sensory 
axons by labeling with     BgTx-488 (green) before fi  xation 
(  Fig. 2 A  ). Treating WT sensory neurons with B4-ECD for 
24 h led to an increase in the number of     BgTx-488 clusters on 
the axonal surface (from 6.47   ±   0.69 clusters/100   μ  m in control 
cultures to 10.38   ±   1.59 clusters/100   μ  m;   Fig. 2 B  ). When we 
repeated the experiment using sensory neurons from Type III 
Nrg1 
   /     embryos, there was no signifi  cant change in the num-
ber of     BgTx-488 clusters on mutant axons (from 3.07   ±   0.72 
clusters/100   μ  m in control cultures to 2.74   ±   1.14 clusters/100   μ  m 
in B4-ECD treated). This effect did not result from general 
changes in the levels of surface proteins, as we did not detect a 
change in the axonal surface levels of TrkA in response to a 
24-h B4-ECD treatment (Fig. S1, E and F). 
  We next asked how soon after B4-ECD treatment the 
increase in surface     7* nAChRs was seen. In sensory neurons 
treated with B4-ECD, we detected an increase in the surface 
expression of     7* nAChR clusters along axons within 1 h, 
  Figure 1.       Decreased     surface expression of 
    7* nAChRs along axons of Type III Nrg1 
    /      
sensory neurons.   Sensory ganglia were ex-
tirpated from embryonic day (E) 14.5 WT 
or Type III Nrg1 
    /      embryos and plated as 
explants. After 2 d in vitro, neurons were la-
beled for surface     7* nAChRs with     BgTx-488 
(green). Neurons were ﬁ  xed,  permeabilized, 
and stained for Type III Nrg1 (red) and NF 
protein (blue). (A) Representative micrographs 
of     BgTx-488 clusters along NF-positive axons 
of WT and Type III Nrg1 
    /      sensory neurons 
at 2 d in vitro. Type III Nrg1 staining was de-
tected along WT (a) but not Type III Nrg1 
    /      
(d) axons. Fewer surface     BgTx-488 clusters 
were detected along mutant axons (e) as com-
pared with WT (b). Confocal images were 
acquired from a 100  ×   oil objective. Bar, 5   μ  m. 
(B) Quantiﬁ  cation of surface     BgTx-488 clus-
ters per 100   μ  m of axonal length revealed 
an     50% reduction of clusters along mutant 
axons. The graph shows means   ±   SEM. Data 
were pooled from three independent experi-
ments. Statistical signiﬁ   cance determined by 
ANOVA. *, P   <   0.001 (Statview). (C) Quanti-
ﬁ  cation of the surface     BgTx-488 cluster area. 
Loss of Type III Nrg1 expression resulted in an 
    35% reduction of     BgTx-488 cluster area. 
Data pooled from three independent experi-
ments were analyzed using nonparametric sta-
tistics and presented as box plots (see Materials and methods). Statistical signiﬁ  cance was determined by the Kolmogorov-Smirnov Test. *, P   <   0.0001 
(Statview). (D) Pretreatment of sensory neurons with 1   μ  M of nicotine (Nic; b and e) or 5   μ  M methyllycaconitine (MLA; c and f) prevents surface     BgTx-488 
labeling along axons. Bar, 10   μ  m. (E) Immunoblot analysis of total     7 subunit protein levels in sensory neurons from E14.5 WT, Type III Nrg1 
+/     , and Type III 
Nrg1 
    /      embryos cultured for 2 d in vitro (a). MAPK1/2 probing in the bottom panel shows equal lysate loading. Immunoblots of total     7 subunit protein lev-
els in brain extracts from WT or     7 nAChR 
    /      embryos are also shown (b). Glyceraldehyde 3-phosphate dehydrogenase probing in the bottom panel shows 
equal lysate loading (b). (F) In WT sensory neurons, nicotine application (1   μ  M for 1 min) resulted in an increased internal concentration of Ca 
2+   (indicated 
in pseudo color; described in Materials and methods). The white arrowhead highlights an axonal region affected by nicotine. Bar, 10   μ  m. (G) Changes in 
internal concentration of Ca 
2+   in response to application of nicotine in WT and mutant axons are plotted. Note that 100 nM     BgTx completely eliminated the 
response to nicotine in WT axons and that sensory axons from Type III Nrg1 
    /      animals did not respond to nicotine. Data are from two independent experi-
ments. The graph shows means   ±   SEM. Statistical signiﬁ  cance was determined by ANOVA with post-hoc Fisher  ’  s PLSD test. *, P   <   0.0001 (Statview).     JCB • VOLUME 181 • NUMBER 3 • 2008  514
 Surface     7* nAChRs were quantifi  ed by  
125 I-  BgTx  la-
beling in live in vitro preparations of chick sensory neurons and, 
in parallel, the total pool of     7* nAChRs was quantifi  ed by 
 
125 I-   BgTx binding after permeabilization with 0.5% saponin 
(  Fig. 3 A  ). Under basal conditions,     12% of the total    7* 
nAChRs were on the surface, which is similar to prior results 
emphasizing the large internal pools of nAChRs in neurons 
(  Cho et al., 2005  ). After a 24-h treatment with B4-ECD, we ob-
served an     2.7-fold increase in surface  
125 I-   BgTx binding. In 
B4-ECD – stimulated  neurons,     30% of the     7* nAChRs were 
at the surface, but the total pool of  
125 I-  BgTx – labeled  sites 
was not changed. These results are consistent with Type III 
Nrg1 back signaling inducing a relocalization of    7*  nAChRs 
from pre  existing internal pools to clusters along the axonal sur-
face. Results on increased surface versus total    7*  nAChRs 
were confi  rmed by immunoblot assay (  Fig. 3 B  ). These results 
indicate that in sensory neurons, Type III Nrg1, acting as a recep-
tor, can increase axonal surface     7* nAChRs without signifi  -
cantly increasing the size of the total     7* nAChR pool. 
  To extend our examination of the idea that Type III Nrg1 
back signaling stimulates insertion of preexisting   7* nAChRs 
Collectively, these results indicate that in sensory neurons, 
Type III Nrg1, acting as a receptor for B4-ECD, regulates the 
surface expression of     7* nAChR, whereas activation of ErbB 
tyrosine kinases does not. 
  Stimulation of Type III Nrg1 back signaling 
increases surface expression of     7* 
nAChRs in the absence of new 
protein synthesis 
  Stimulation of Type III Nrg1 back signaling elicits a transcrip-
tional response mediated by the Nrg1 intracellular domain (  Bao 
et al., 2003, 2004  ). To determine if Type III Nrg1  –  dependent 
regulation of axonal     7* nAChR levels resulted from Nrg1 
intracellular domain  –  induced synthesis of     7 and/or changes 
in     7* nAChR surface expression along axons, we compared 
measures of total (surface and internal) neuronal  
125 I-  BgTx 
binding (  Fig. 3 A  ) and total immunoreactive    7  nAChR  protein 
( Fig.  3  B  )   in sensory neurons treated with B2-ECD (control) or 
B4-ECD for 24 h. We also asked whether B4-ECD treatment 
increased surface     7* nAChR levels in the presence of a protein 
synthesis inhibitor (  Fig. 3, C  –  E  ). 
  Figure 2.       Type III Nrg1 back-signaling increases the surface 
expression of     7* nAChRs.   E14.5 WT or Type III Nrg1 
    /      
DRG explants were treated with B2-ECD (control) or B4-ECD 
for 24 h. Neurons were labeled for surface     7* nAChRs with 
    BgTx-488 (green), ﬁ   xed, permeabilized, and labeled for 
NF protein (blue). (A) Representative micrographs of axons 
from WT (a and b) or Type III Nrg1 
    /      (c and d) sensory 
neurons under control (a and c) versus B4-ECD (b and d) 
conditions. B4-ECD treatment increased the number of sur-
face     BgTx-488 clusters along NF-positive processes of WT 
neurons (b). Linescans of ﬂ   uorescence intensity proﬁ  le  for 
    BgTx-488 staining along representative axons (see Mate-
rials and methods). Bar, 5   μ  m. (B) Quantiﬁ  cation of surface 
    BgTx-488 clusters along NF-positive axons from WT ver-
sus Type III Nrg1 
    /      DRG explants treated with either B2-
ECD (control) or B4-ECD for 24 h. In WT cultures, B4-ECD 
treatment induced an     1.6-fold increase in surface     BgTx 
clusters along NF-positive axons compared with the control. 
There was no detectable change in     BgTx clusters along 
axons of Type III Nrg1 
    /      neurons. The graph shows means   ±   
SEM. Data were pooled from three independent experi-
ments. Statistical signiﬁ   cance was determined by ANOVA 
with post-hoc Fisher  ’  s PLSD test. *, P   <   0.03; **, P   <   0.001 
(Statview). (C) After 2 d in vitro, dissociated sensory neurons 
from E11 chick embryos were treated with B2-ECD (control) 
or B4-ECD for 1, 2, 6, or 12 h and labeled as described in A. 
Axonal surface     BgTx-488 clusters were quantiﬁ  ed. Data 
were pooled from three independent experiments. The graph 
shows means   ±   SEM. Statistical signiﬁ  cance was determined 
by ANOVA with post-hoc Fisher  ’  s PLSD test. *, P   <   0.05; **, 
P   <   0.01; ***, P   <   0.001 (Statview). (D) Axonal-bound B4-
ECD and     BgTx-488 were detected in puncta along axons 
treated with B4-ECD (b, d, and e). Sensory neurons from 
E14.5 WT mouse embryos were cultured for 2 d in vitro 
and treated with B2-ECD (control) or B4-ECD for 1 h. Before 
ﬁ   xation, surface     7* nAChRs and axonal-bound B2-ECD 
(control) or B4-ECD were labeled with     BgTx-488 (green) 
and an antibody against the human Fc domain (anti-Fc; red), 
respectively. c and d and e are magniﬁ  cations of the areas 
shown in dotted squares in a and b, respectively. Bar: (a and b) 
5   μ  m; (c  –  e) 1   μ  m. (E) Sensory neurons from E11 chick em-
bryos were treated with B2-ECD (control), B4-ECD, or soluble 
Nrg1     peptide (Nrg1-ECD) for 1 h. In parallel, neurons pretreated with an ErbB tyrosine kinase inhibitor (ErbB inh.) for 45 min were treated with B2-ECD, 
B4-ECD, or Nrg1-ECD for 1 h. Neurons were labeled as described in A, and surface     BgTx-488 clusters along axons were quantiﬁ  ed. Data were pooled 
from three independent experiments. The graph shows means   ±   SEM. Statistical signiﬁ  cance was determined by ANOVA with post-hoc Fisher  ’  s PLSD test. 
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into the axonal membrane, we repeated the B4-ECD stimula-
tion of dispersed sensory neurons in the presence of the pro-
tein synthesis inhibitor cycloheximide (CHX;   Fig. 3, C  –  E  ). 
Neurons were pretreated with 10   μ  g/ml CHX for 45 min and 
then stimulated for an additional hour with either B2-ECD 
(control) or B4-ECD. Neither the B4-ECD  –  induced increase 
in the number of surface     BgTx-488 clusters (  Fig. 3 D  ) nor 
the increase in cluster area (  Fig. 3 E  ) were affected by the 
CHX pretreatment (CHX, 9.72   ±   1.65 clusters/100-  μ  m axonal 
length; CHX + B4-ECD, 19.96   ±   2.83 clusters/100-  μ  m axonal 
length; CHX, 0.23   ±   0.02   μ  m 
2  ; and CHX + B4-ECD, 0.32   ±   
0.01   μ  m 
2  ). Thus, the increase in surface     7* nAChRs resulted 
from a redistribution of preexisting receptors rather than from 
new receptor synthesis. 
  Type III Nrg1 back signaling increases 
surface expression of     7* nAChRs in the 
absence of endocytosis 
  Prior studies have shown that endocytosis can alter the surface 
expression of neurotransmitter receptors (  Man et al., 2007  ;   Xia 
et al., 2007  ). Using a pharmacological inhibitor of endocytosis, 
phenylarsine oxide (PAO;   Hertel et al., 1985  ), we investigated 
whether B4-ECD  –  mediated increase in the surface expression 
of     7* nAChR clusters was caused by alterations in receptor 
endocytosis. We applied PAO to sensory neurons for 45 min 
before B2-ECD (control) or B4-ECD treatment. Although PAO 
did not signifi  cantly alter the number of surface    7*  nAChR 
clusters along axons under control conditions, it signifi  cantly 
increased the area of the clusters (from 0.2   ±   0.01   μ  m 
2   under 
control conditions to 0.29   ±   0.03   μ  m 
2   after PAO treatment;   Fig. 
4 C  ). After B4-ECD treatment for 1 h, we detected an increase 
in both the number and area of surface     7* nAChR clusters 
along axons when endocytosis was blocked (  Fig. 4 B  , PAO, 
16.03   ±   2.69 clusters/100-  μ  m axonal length; and PAO + B4-
ECD, 29.77   ±   3.41 clusters/100-  μ  m axonal length;   Fig. 4 C  , 
PAO, 0.29   ±   0.03   μ  m 
2  ; and PAO + B4-ECD, 0.34   ±   0.04   μ  m 
2 ). 
Based on our fi  ndings, we conclude that the increase in surface 
    7* nAChRs results from an increase in membrane insertion 
rather than a decrease in endocytosis. 
  Type III Nrg1 back signaling activates a 
PtdIns 3K signaling pathway 
  Our main objective in the following experiments was to test for 
signaling pathways activated downstream of Type III Nrg1 that 
might direct membrane targeting of     7* nAChRs. Because of 
the substantial evidence that PtdIns 3K signaling is a major regu -
lator of membrane protein traffi  cking (  Tengholm and Meyer, 
2002  ;   Man et al., 2003  ;   Viard et al., 2004  ;   Chae et al., 2005  ), we 
asked whether stimulation of Type III Nrg1 back signaling acti-
vated PtdIns 3K signaling. Sensory neurons were stimulated with 
B2-ECD (control) or B4-ECD for 5 min and then labeled with an 
antibody recognizing the PtdIns 3K product, phosphatidylinositol 
  Figure 3.       Type III Nrg1 back signaling increases the surface expression 
of     7* nAChRs in the absence of protein synthesis.   Dissociated sensory 
neurons from E11 chick embryos were cultured for 2 d in vitro and treated 
with either B2-ECD (control) or B4-ECD for 1 or 24 h. (A) Quantiﬁ  cation 
of surface or total pools of     7* nAChR by  
125  I-    BgTx radiolabeling in 
sensory neurons treated with either B2-ECD (control) or B4-ECD for 24 h. 
In response to a 24-h B4-ECD treatment, we detected an     2.7-fold 
increase in surface  
125  I-    BgTx binding compared with control conditions 
(B2-ECD [control], 1,339.15   ±   329.77 cpm; and B4-ECD, 3,562.81   ±   
1,111.19 cpm). B4-ECD treatment did not induce a change in total 
 
125  I-    BgTx binding as compared with the control (B2-ECD [control], 
11,159.74   ±   1,059.79 cpm; and B4-ECD, 12,258.85   ±   580.11 cpm). 
The graph shows means   ±   SEM. Data were pooled from three indepen-
dent experiments with greater than or equal to three wells per condition 
per experiment. Statistical signiﬁ   cance was determined by ANOVA. 
*, P   <   0.05 (Statview). (B) Immunoblot analysis of total     7 subunit protein 
in sensory neurons treated with B2-ECD (control) or B4-ECD treatment for 
24 h. In response to B4-ECD treatment, we did not detect a difference in 
total     7 subunit protein. NF  M   probing in bottom panel shows equivalent 
lysate loading. (C) Sensory neurons were treated with B2-ECD (control) 
or B4-ECD for 1 h. In parallel, neurons pretreated with CHX for 45 min 
were treated with B2-ECD or B4-ECD for 1 h. Neurons were labeled with 
    BgTx-488 (green), ﬁ  xed, permeabilized, and colabeled for NF protein 
(blue). CHX treatment (c and d) did not affect either the basal number 
of     BgTx-488 clusters on control neurons (c) or the response to B4-ECD 
(d). Linescans of ﬂ  uorescence intensity proﬁ  les of     BgTx-488 along rep-
resentative axons (see Materials and methods) are shown. Bar, 5   μ  m. 
(D) Quantiﬁ  cation of surface     BgTx-488 clusters along NF-labeled axons. 
B4-ECD treatment induced an     1.9-fold increase in surface     BgTx-488 
clusters along axons, and B4-ECD treatment in the presence of CHX in-
duced an     2.1-fold increase. Data were pooled from three independent 
experiments. The graph shows means   ±   SEM. Statistical signiﬁ  cance 
was determined by ANOVA with post-hoc Fisher  ’  s PLSD test. *, P = 0.01; 
**, P   <   0.0001 (Statview). (E) Quantiﬁ  cation of surface     BgTx-488 cluster 
area. B4-ECD treatment in the presence or absence of CHX induced an 
increase in     BgTx-488 cluster area. Data pooled from three independent 
experiments were analyzed using nonparametric statistics and presented 
as box plots (see Materials and methods). Statistical signiﬁ  cance was de-
termined by the Kolmogorov-Smirnov Test. *, P   ≤   0.0001 (Statview).     
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(Fig. S3 C) and NGF/TrkA signaling   (  Fig. S3 D) were blocked. 
Thus, we conclude that Type III Nrg1 back signaling rapidly 
and locally activates PtdIns 3K signaling. 
  PtdIns 3K signaling activated by 
Type III Nrg1 back signaling is required for 
increased     7 nAChR surface expression 
  We tested whether PtdIns 3K activation is required for Type III 
Nrg1 – mediated  changes  in     7* nAChR surface expression 
(  Fig. 6  ). We treated dispersed sensory neurons with either B2-ECD 
(control) or B4-ECD for 1 h in the presence of 500 nM of the 
PtdIns 3K inhibitor WM. Surface     7* nAChR clusters were la-
beled with     BgTx-488 (green), after which neurons were fi  xed 
and immunolabeled with an antibody against NF protein (blue; 
  Fig. 6 A  ). In response to the B4-ECD treatment, we detected a 
signifi  cant increase in the number (  Fig. 6 B  ) and area (  Fig. 6 C  ) 
of     BgTx-488 clusters along NF-positive processes. WM treat-
ment alone did not affect the number of     BgTx-488 clusters but 
did inhibit the response to B4-ECD, preventing the increase in 
the number of axonal surface    7*nAChRs  ( Fig.  6  B ,  B2-ECD 
[control], 9.08   ±   1.53 clusters/100-  μ  m axonal length; B4-ECD, 
17.41   ±   1.48 clusters/100-  μ  m axonal length; WM, 9.58   ±   2.17 
clusters/100-  μ  m axonal length; and WM + B4-ECD, 10.75   ±   
1.27 clusters/100-  μ  m axonal length). Pretreatment with 5   μ  M of 
a small molecule inhibitor of Akt kinase activity (Akt inhibitor 
[Akt inh.]) also prevented the response to B4-ECD (  Fig. 6 B  , 
Akt inh., 10.33   ±   1.42 clusters/100-  μ  m axonal length; and Akt 
inh. + B4-ECD, 8.48   ±   1.58 clusters/100-  μ  m axonal length). 
Both WM and Akt inh. prevented the increase in surface    BgTx 
cluster area in response to B4-ECD treatment (  Fig. 6 C  , B2-
ECD [control], 0.25   ±   0.02   μ  m 
2  ; B4-ECD, 0.35   ±   0.02   μ  m 
2 ; 
WM, 0.22   ±   0.02   μ  m 
2  ; WM + B4-ECD, 0.23   ±   0.02   μ  m 
2 ;  Akt 
inh., 0.22   ±   0.02   μ  m 
2  ; and Akt inh. + B4-ECD, 0.25   ±   0.02   μ  m 
2 ). 
We conclude that Type III Nrg1 back signaling activates PtdIns 
3K signaling and that PtdIns 3K/Akt activities are required 
for Type III Nrg1  –  induced targeting of     7* nAChRs to the 
axonal surface. 
  Discussion 
  Nrg1-ErbB signaling plays an important role in synaptic plas-
ticity, in part by regulating the levels of pre- and postsynaptic 
receptors and ion channels (  Ozaki et al., 1997  ;   Huang et al., 
2000  ;   Chae et al., 2005  ;   Gu et al., 2005  ;   Kwon et al., 2005  ; 
  Bjarnadottir et al., 2007  ;   Li et al., 2007  ;   Role and Talmage, 
2007  ;   Woo et al., 2007  ), including nAChRs containing the    7 
subunit (  Yang et al., 1998  ;   Liu et al., 2001  ;   Kawai et al., 2002  ; 
  Chang and Fischbach, 2006  ). In this study we demonstrate that 
Type III Nrg1, acting as a receptor for ErbB4, controls the inser-
tion of     7* nAChRs into axonal membranes. Type III Nrg1 
accomplishes this by activating a local PtdIns 3K signaling 
pathway. These fi  ndings expand the repertoire of identifi  ed 
mechanisms by which Type III Nrg1 bidirectional signaling 
contributes to the establishment and the maturation of func-
tional presynaptic terminals (  Bao et al., 2003, 2004  ). Our major 
fi  ndings supporting this conclusion are the following: genetic 
disruption of Type III Nrg1 affects surface    7*  nAChR  levels; 
3,4,5 trisphosphate (PIP  3  ;   Fig. 5 A  ). In neurons treated with 
B4-ECD, we detected an increase in PIP  3   staining along tau-
positive axons. This response was comparable to that seen after 
acute treatment with 100 ng/ml NGF and was completely 
blocked in cultures pretreated with 500 nM of the PtdIns 3K in-
hibitor wortmannin (WM). 
  As an additional test of whether Type III Nrg1 back sig-
naling activates a PtdIns 3K signaling pathway, we measured 
the phosphorylation status of the PtdIns 3K effector kinase Akt 
in WT and Type III Nrg1 
   /     sensory neurons (  Fig. 5, B  –  D  ; and 
Fig. S3, A  –  D, available at http://www.jcb.org/cgi/content/full/
jcb.200710037/DC1). After a 10-min B4-ECD treatment, we 
detected phospho-Akt in puncta along B4-ECD  –  bound axons 
of WT neurons; however, we did not detect a change in phospho-
Akt in axons from mutant explants (  Fig. 5, C and D  ). The re-
sponse to B4-ECD treatment was selective for the neurons and 
for the PtdIns 3K  –  Akt pathway. There was no activation of Akt 
in nonneuronal cells (Fig. S3 A) and there was no activation of 
MAPK in neurons (Fig. S3 E). Additionally, B4-ECD treatment 
was able to induce activation of Akt when ErbB kinase activity 
  Figure 4.       Type III Nrg1 back signaling increases     7* nAChRs cluster area 
in the absence of endocytosis.   Dissociated sensory neurons from E11 chick 
embryos were treated with B2-ECD (control) or B4-ECD for 1 h. In paral-
lel, neurons were treated with PAO for 45 min and treated with B2-ECD 
or B4-ECD for an additional hour. Neurons were labeled with     BgTx-488 
(green), ﬁ  xed, permeabilized, and colabeled for NF protein (blue). (A) Rep-
resentative micrographs of     BgTx-488 staining along NF-positive axons. 
B4-ECD treatment increased surface     BgTx-488 clusters in the presence of 
PAO (d). Linescans of ﬂ  uorescence intensity proﬁ  les of     BgTx-488 along 
representative axons (see Materials and methods) are shown. Bar, 5   μ  m. 
(B) Quantiﬁ  cation of surface     BgTx-488 clusters along NF-labeled axons. 
B4-ECD treatment in the presence and absence of PAO induced     1.7 
and 1.9 increases in surface     BgTx-488 clusters along axons, respectively. 
Data were pooled from two independent experiments. The graph shows 
means   ±   SEM. Statistical signiﬁ  cance was determined by ANOVA with 
post-hoc Fisher  ’  s PLSD test. *, P   <   0.03 (Statview). (C) Quantiﬁ  cation of sur-
face     BgTx-488 cluster area. B4-ECD treatment in the presence or absence 
of PAO induced an increase in     BgTx-488 cluster area. Data pooled from 
two independent experiments were analyzed using nonparametric statis-
tics and presented as box plots (see Materials and methods). Statistical 
signiﬁ  cance was determined by the Kolmogorov-Smirnov Test. *, P = 0.03; 
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full/jcb.200710037/DC1), by the ErbB3 present on glia, or after 
depolarization (  Bao et al., 2003, 2004  ), locally regulates the 
levels of presynaptic     7* nAChR surface expression. As a 
result, Type III Nrg1 back signaling, by regulating presynaptic 
    7* nAChRs, alters the magnitude of acetylcholine modulation 
of neurotransmitter release (  MacDermott et al., 1999  ;   Jones and 
Wonnacott, 2004  ). 
  We demonstrate that stimulating Type III Nrg1 activates a 
PtdIns 3K signaling pathway and that PtdIns 3K and Akt activ-
ity are required for increased surface expression of   7* nAChRs. 
At present, we do not know the molecular details of how 
Type III Nrg1 communicates with the PtdIns 3K signaling path-
way or what Akt substrates regulate     7* nAChR traffi  cking. 
Type III Nrg1 functioning as a receptor can regulate insertion of 
preformed     7* nAChRs into axonal surfaces; and Type III Nrg1 
activates an axonal PtdIns 3K signaling pathway that mediates 
increased levels of surface    7*  nAChRs. 
  Prior work has shown that presynaptic Type III Nrg1 is 
critical for establishing stable interactions with postsynaptic 
partners and, ultimately, for the survival of neuromuscular syn-
apses as well as for glia development and myelination (  Wolpowitz 
et al., 2000  ;   Michailov et al., 2004  ;   Taveggia et al., 2005  ; 
  Chen et al., 2006  ). Our studies demonstrate that Type III Nrg1 
acts as a presynaptic signaling receptor. Activation of pre-
synaptic Type III Nrg1 signaling, either by postsynaptic ErbB4 
(as shown in Fig. S4, available at http://www.jcb.org/cgi/content/
  Figure 5.       Type III Nrg1 back signaling activates the PtdIns 3K signaling pathway.   (A) Dissociated sensory neurons from E11 chick embryos were treated 
for 5 min with B2-ECD (control), B4-ECD, 50 ng/ml NGF, or 10 ng/ml of soluble Nrg1     peptide (Nrg1-ECD). In parallel, neurons were treated with 
WM for 45 min before B4-ECD stimulation (WM + B4-ECD). Neurons were ﬁ  xed, permeabilized, and costained for PIP  3   (red) and tau protein (blue) to 
label axons. Both B4-ECD (g) and NGF (i) treatment induced puncta of PIP  3   along tau-positive axons. Neither B4-ECD stimulation in the presence of WM 
(c and h) nor that of Nrg1-ECD (e and j) induced an increase in PIP  3  . Confocal images were obtained with a 40  ×   oil objective. Bar, 10   μ  m. (B) Immunoblot 
analysis of phospho-Akt (Ser 473) in WT or Type III Nrg1 
    /      sensory neurons treated with either B2-ECD (control) or B4-ECD for 10 min. In WT neurons, 
B4-ECD treatment induced an approximately threefold increase in phospho-Akt, whereas no response was detected in mutant neurons. Total Akt in the 
bottom panel shows equal lysate loading. The bar graph represents phospho-Akt normalized to total Akt immunoreactive bands. Data are representative 
of three independent experiments. The graph shows means   ±   SEM. Statistical signiﬁ  cance was determined by ANOVA with post-hoc Fisher  ’  s PLSD test. 
*, P   <   0.002 (Statview). (C and D) E14.5 WT (a and b) or Type III Nrg1 
    /      (c and d) DRG explants were treated with B2-ECD (control) or B4-ECD for 
10 min. Surface-bound B4-ECD or B2-ECD were labeled with an antibody against the human Fc domain (anti-Fc; green) before ﬁ  xation. Neurons were 
ﬁ  xed, permeabilized, and stained for phospho-Akt (red) and NF protein (blue). B4-ECD treatment increased phospho-Akt along Fc-positive axons of WT 
neurons (b and D) but did not do so along axons of mutant neurons (d). Note the close proximity of anti-FC and phospho-Akt puncta in the high-power 
micrograph shown in e. The asterisk denotes an axon negative for both anti-Fc and phospho-Akt immunolabeling (c). A 63  ×   oil objective was used (a  –  d). 
Confocal imaging was obtained with a 100  ×   oil objective (D). Bar: (a  –  d)     10   μ  m; (D) 5   μ  m. (E) Quantiﬁ  cation of the average ﬂ  uorescence intensity (AFI) 
of phospho-Akt along axons of WT or Type III Nrg1 
    /      sensory neurons treated with B2-ECD (control) or B4-ECD for 10 min or 1, 2, or 6 h (see Materials 
and methods). Along WT axons, B4-ECD treatment induced increases in phospho-Akt. Along axons of mutant neurons, we did not detect an increase in 
phospho-Akt in response to B4-ECD treatment. The graph shows means   ±   SEM. Data are from three independent experiments. Statistical signiﬁ  cance was 
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isoxazolepropionic acid receptors (  Man et al., 2003  ). An in-
creased understanding of the molecular mechanisms that regulate 
traffi  cking of these proteins is certain to inform our further stud-
ies on presynaptic     7* nAChR targeting. 
  We have used     BgTx binding to identify both surface and 
internal pools of     7* nAChRs.     BgTx binding requires at least 
partial assembly of     7 subunits into pentamers (  Mitra et al., 
2001  ). Because we do not see effects of Type III Nrg1 back sig-
naling on     BgTx binding in permeabilized cells, it is unlikely 
that the early stages of assembling     7 subunits into functional 
receptors are targeted by back signaling. Assembly of    7* 
nAChRs and traffi  cking of     7* nAChRs through the exocytic 
pathway can be infl  uenced by synaptic scaffolding proteins 
such as PICK1 (  Baer et al., 2007  ), reversible palmitoylation (of 
    7* nAChRs by itself;   Drisdel et al., 2004  ), tyrosine residues 
on unidentifi  ed proteins (  Cho et al., 2005  ), and chronic nicotine 
(  Marks et al., 1992  ). Any of these mechanisms might represent 
convergent targets with Type III Nrg1  –  PtdIns 3K signaling for 
infl  uencing the rate of ER/Golgi to plasma membrane traffi  ck-
ing of    7*  nAChRs. 
  Targeting nAChRs to presynaptic locales is an important 
part of establishing a plastic synapse. The     7* nAChRs in par-
ticular play a critical role in sustained modulation of neurotrans-
mitter release (  McGehee et al., 1995  ;   Girod et al., 2000  ). 
Defi  cits in Type III Nrg1 signaling compromise the ability of 
nicotine to elicit sustained glutamatergic transmission at ventral 
hippocampal to nucleus accumbens synapses (Du, C., C. Zhong, 
M. Hancock, D.A. Talmage, and L.W. Role. 2004. Society for 
Neuroscience 34th Annual Meeting; unpublished data) and, 
based on the results presented here, we would predict a similar 
effect on nicotine/acetylcholine modulation of glutamate re-
lease from primary sensory afferents in the dorsal spinal cord 
(  Genzen and McGehee, 2003  ). From the present data, we can-
not say whether the requirement for Type III Nrg1 signaling is 
limited to developmental synaptogenesis or whether it contin-
ues to affect presynaptic     7* nAChR targeting to established 
synapses, contributing to the maintenance of synaptic plasticity 
throughout the lifespan. If Type III Nrg1 signaling does con-
tinue to regulate presynaptic levels of     7* nAChR or other re-
ceptors, then modulation of Type III Nrg1 signaling in sensory 
axons could contribute to adaptive physiological changes or to 
pathological changes in sensory transduction (  Bermingham-
McDonogh et al., 1997  ;   Kerber et al., 2003  ). 
  There are interesting parallels between our fi  ndings and 
pathophysiological studies. Increasing evidence from genetic 
linkage studies has identifi  ed both the   NRG1   ( Stefansson  et  al., 
2002  ;   Harrison and Law, 2006  ) and the    7  nAChR  gene 
  CHRNA7   (  Freedman et al., 2001  ;   Leonard and Freedman, 2006 ) 
as susceptibility genes for schizophrenia. Postmortem studies 
have demonstrated decreased levels of     BgTx binding in the 
hippocampus of schizophrenic patients (  Freedman et al., 1995  ; 
  Breese et al., 2000  ), and decreased levels of     7 mRNA and 
    BgTx binding in dorsal lateral prefrontal cortex of schizo-
phrenic brain are associated with risk alleles at the   NRG1   locus 
(  Mathew et al., 2007  ). It is worth noting that these risk alleles at 
the   NRG1   locus also have been associated with increased ex-
pression of Type I and IV Nrg1 (  Law et al., 2006  ). This raises 
  Figure 6.       PtdIns 3K  —  Akt signaling activated by Type III Nrg1 back sig-
naling is required for increased     7* nAChR surface expression.   Dissoci-
ated sensory neurons from E11 chick embryos were treated with B2-ECD 
(control) or B4-ECD for 1 h. In parallel, neurons were pretreated with WM 
or an Akt inh. for 45 min before treatment with B2-ECD or B4-ECD for 
an additional hour. Neurons were labeled for surface     7* nAChRs with 
    BgTx-488 (green), ﬁ  xed, permeabilized, and costained for NF protein 
(blue). (A) Representative micrographs of     BgTx-488 staining along NF-
positive axons. B4-ECD treatment increased surface     BgTx-488 clusters 
(b), which did not occur in the presence of WM (d). Linescans of ﬂ  uo-
rescence intensity proﬁ  les of     BgTx-488 along representative axons (see 
Materials and methods) are shown. Bar, 5   μ  m. (B) Quantiﬁ  cation of sur-
face     BgTx-488 clusters along sensory neuron axons represented in A. 
B4-ECD treatment induced an     1.9-fold increase of surface     BgTx-488 
clusters but not in the presence of WM or Akt inh. Data were pooled from 
three independent experiments. The graph shows means   ±   SEM. Statistical 
signiﬁ  cance was determined by ANOVA with post-hoc Fisher  ’  s PLSD test. 
*, P   <   0.0001 (Statview). (C) Quantiﬁ  cation of surface     BgTx-488 cluster 
area. B4-ECD treatment induced an increase in     BgTx-488 cluster area but 
not in the presence of WM or Akt inh. Data pooled from three independent 
experiments were analyzed using nonparametric statistics and presented 
as box plots (see Materials and methods). Statistical signiﬁ  cance  deter-
mined by the Kolmogorov-Smirnov Test. *, P = 0.0001 (Statview).     
The intracellular domains of Type III Nrg1 lack known func-
tional motifs that could mediate protein  –  protein interactions. 
  PtdIns 3K and its product PIP  3   are ubiquitous signaling 
molecules that link cell surface receptors to intracellular down-
stream effectors. PtdIns 3K signaling regulates the traffi  cking 
of several cell surface proteins, such as glucose transporter 4 
(  Tengholm and Meyer, 2002  ), excitatory amino acid carrier 1 
glutamate transporter (  Davis et al., 1998  ), calcium channels 
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maximum intensity and greater than or equal to four contiguous pixels 
(  Kawai et al., 2002  ). To determine nonspeciﬁ   c binding, cultures were 
treated with 1   μ  M of nicotine or 5   μ  M methyllycaconitine before labeling. 
For each experiment, nonspeciﬁ  c labeling was   ≤  12% and was subtracted 
from all counts. Linescans with widths of 10 contiguous pixels were ob-
tained using Metamorph software. 
  To quantify Akt activation along axons, neurons were stained with 
antibodies against phospho-Akt and NF to label axons. 15  –  20 axons per 
condition were analyzed in each experiment. The AFI of phospho-Akt 
along NF-positive processes was measured using MetaMorph software. 
The AFI of two to three randomly selected regions for each condition 
were measured as background AFI and subtracted from all measurements. 
To compare results between independent experiments, the mean AFI from 
different conditions in each independent experiment was normalized to the 
control AFI and is expressed as fold increase. 
  Ca 
2+   imaging 
  After 3 d in vitro, DRG explants were rinsed with HBSS, loaded with Fluo-3 
Ca 
2+   binding dye (Invitrogen) dissolved in HBSS for 30 min at 37  °  C, and 
rinsed for 30 min at 37  °  C in HBSS. The coverslip was placed on a 
perfusion-equipped stage and perfused at a rate of 0.5 ml/min with HBSS 
containing 2   μ  M tetrodotoxin, 10   μ  M bicuculin, 50   μ  M   D-(    )  -2amino-5-
phosphono-valeric acid and 20   μ  M CNQX (Sigma-Aldrich). Images were 
captured every 5 s using a spinning disc confocal microscope (DSU; Olympus) 
equipped with a UPlanSApo objective (60  ×   water with 1.4 NA), electron-
multiplying charge-coupled device camera (Hamamatsu), and Slidebook 
software (Version 4; Olympus). After acquiring images for 1 min, 1   μ  M of 
nicotine was focally applied by pressure ejection for 60 s and the explants 
were imaged for another 4 min. After a 1-  μ  M nicotine application, ﬂ  uo-
rescence intensity within deﬁ  ned axonal regions was quantiﬁ  ed with Meta-
Morph software. 
   
125  I-    BgTx binding assay 
  After 2 d in vitro, dispersed chick sensory neurons were treated with 2 nM 
of soluble B2-ECD or B4-ECD for 24 h. 6 nM  
125  I-    BgTx (2,000 Ci/  μ  mol; 
GE Healthcare) was added directly to the media for the ﬁ  nal 20 min. 
To measure total  
125  I-    BgTx binding, cultures were rinsed three times with PBS 
and permeabilized with 0.5% saponin in 0.2% FAF-BSA/PBS for 30 min 
before incubation with 6 nM  
125  I-    BgTx in 0.2% FAF-BSA/PBS for 2 h on 
ice. For both surface and total labeling, nonspeciﬁ  c binding was assessed 
by including 1   μ  M     BgTx (Sigma-Aldrich) during the labeling with  
125  I-
    BgTx. After labeling, cells were washed and solubilized in 1 N NaOH, 
and bound  
125  I-    BgTx was quantiﬁ  ed with a      counter. Nonspeciﬁ  c bind-
ing was subtracted. 
  Immunoblotting 
  Neurons were lysed in RIPA buffer (Thermo Fisher Scientiﬁ  c) supplemented 
with 10 mM DTT, protease inhibitors (Sigma-Aldrich), and phosphatase in-
hibitors (Thermo Fisher Scientiﬁ  c). Lysates (phospho-Akt, 25   μ  g;     7, 40   μ  g) 
were separated on 10% SDS-PAGE gels and transferred to nitrocellulose 
ﬁ  lters. Filters were blocked in 5% milk in 0.1% Tween-20 TBS solution at RT 
for 2 h before overnight incubation in primary antibody solutions in 5% 
BSA or milk in Tween-20 TBS solution at 4  °  C (anti-    7 nAChR subunit 
[1:500; Santa Cruz Biotechnology, Inc.], anti-MAPK [1:5,000; Millipore], 
anti-glyceraldehyde 3-phosphate dehydrogenase [1:10,000; Millipore], 
anti  –  NF M [1:7,500; Millipore), anti  –  phospho-Akt [1:500; Cell Signaling 
Technology], and anti-Akt [1:1,000; Cell Signaling Technology]). Detection 
was performed using Alexa Fluor 680 (Invitrogen) or IRDye-800 (Rockland 
Immunochemicals) secondary antibodies and an Odyssey Infrared Imag-
ing System (Version 2.1; LI-COR Biosciences). 
  Transferrin recycling 
  After 2  –  4 d in vitro, WT or Type III Nrg1 
    /      sensory neurons were serum 
starved for 25 min in serum-free MEM containing 0.5% BSA. Neurons 
were incubated with 10   μ  g/ml transferrin  –  Alexa 488 (Invitrogen) for 15 min 
in serum-free media, after which cells were rinsed and chased in complete 
media supplemented with 1 mg/ml of unlabeled transferrin (Sigma-
Aldrich). During the chase period, live images of neurons were captured at 
0.5  –  1-  μ  m intervals every 2  –  4 min over a   >  20-min period using a spinning 
disc confocal microscope (DSU; Olympus) equipped with a UPlanSApo 
objective (60  ×   water with 1.4 NA), electron-multiplying charge-coupled 
device camera, and Slidebook software. The AFI of transferrin  –  Alexa 488 
in collapsed z series was measured using MetaMorph software. The AFI of 
two to three randomly selected regions for each condition was measured 
as background AFI and subtracted. The AFI from each time point was nor-
malized to the AFI at t = 0 and is expressed as percentage of initial AFI. 
the possibility that excess levels of soluble Nrg1 peptide dis-
turbs the balance of bidirectional Nrg1-ErbB signaling that serves 
to ensure normal levels of functional    7*  nAChRs. 
  Materials and methods 
  Animals and cell culture 
  DRG explants from E14.5 WT or Type III Nrg1 
    /      mouse embryos 
(  Wolpowitz et al., 2000  ) were dissected and cleaned with forceps to re-
move connective tissue. DRG were plated on glass coverslips (precoated 
with 1 mg/ml poly-  D  -lysine and 100   μ  g/ml laminin) and cultured in MEM 
(Invitrogen) supplemented with 10% FBS, 4 mg/ml glucose, 2 mM   L-  glutamine, 
50 U/ml each of penicillin and streptomycin (Invitrogen), and 40 ng/ml 
    -NGF (Harlan Bioproducts for Science) at 37  °  C for 2 d. DRG from E11 
chick embryos were dispersed and cultured in DME media (Invitrogen) 
supplemented with 5% chick embryonic extract, 10% horse serum, 2 mM 
  L-  glutamine, 50 U/ml penicillin and streptomycin (Invitrogen), and 50 ng/ml 
    -NGF (Harlan Bioproducts for Science) at 37  °  C for 2 d. For PIP  3   and 
phospho-Akt labeling and immunoblotting, culture media was replaced 
with serum-free media 4 h before soluble factor addition. For chick cul-
tures, serum-free media consisted of DME, 1% BSA (Sigma-Aldrich), 2 mM   
L-  glutamine (Invitrogen), insulin-transferrin-selenium supplement (Sigma-
Aldrich) and 50 U/ml each of penicillin and streptomycin. For mouse 
cultures, serum-free media consisted of MEM, 1% BSA, 4 mg/ml glucose, 
2 mM    L-  glutamine, insulin-transferrin-selenium supplement, and 50 U/ml 
each of penicillin and streptomycin. 
  Reagents 
  Where indicated, the following reagents were applied to the cells: 2 nM of 
soluble B2-ECD or B4-ECD (  Bao et al., 2003  ), 50 ng/ml of recombinant 
HRG1-    1 EGF-like domain (R  &  D Systems), 50 ng/ml     -NGF (R  &  D Sys-
tems), 10   μ  g/ml CHX (Sigma-Aldrich), 5   μ  M phenylarsine oxide (Sigma-
Aldrich), 500 nM WM (EMD), 5   μ  M Akt Inh. V (EMD), 2   μ  M each of PD 
158780 and PD 168393 (EMD), and 200 nM TrkA inhibitor (EMD). Inhib-
itors were added to the media for 45 min before soluble factor addition. 
  Immunoﬂ  uorescence 
  Cells were ﬁ  xed with 4% PFA for 20 min at RT, permeabilized with 0.2% 
Triton X-100 (where indicated) for 5 min at RT, blocked with 10% NDS, 
and incubated with primary antibodies overnight at 4  °  C. The following 
primary antibodies were used: anti-Type III Nrg1 (1:500;   Yang et al., 
1998  ), anti-NF (1:500; Sternberger Monoclonals, Inc.), anti-tau (1:250; 
Sigma-Aldrich), anti-human IgG (Fc-speciﬁ  c; 1:200; Sigma-Aldrich), anti-
PI  3,4,5  P  3   (1:50; Echelon Biosciences Inc.), anti  –  phospho-Akt (1:200; Cell 
Signaling Technology), anti-synaptophysin (1:500; Millipore); anti-vGlut1 
(1:200; Synaptic Systems GmbH), anti-TrkA (1:5,000; gift from L.F. Reichardt, 
University of California, San Francisco, San Francisco, CA), anti-
MAP2 (1:500; Millipore), and anti  –  phospho MAPK (1:1,000; Sigma-Aldrich). 
Cells were washed and incubated in secondary antibodies conjugated to 
Alexa 488 (1:500; Invitrogen), Alexa 594 (1:500; Invitrogen), or anti-
mannobioside carbohydrate antibodies (1:50; Jackson ImmunoResearch 
Laboratories) for 1 h at RT. To label PI  3,4,5  P  3  , slips were treated with Avidin/
Biotin Blocking kit (Vector Laboratories) before incubation in anti-PI  3,4,5  P  3  . 
The primary antibody signal was ampliﬁ  ed by sequential binding with a 
biotinylated anti  –  mouse secondary (1:200; Jackson ImmunoResearch Lab-
oratories) and NeutrAvidin  –  -rhodamine red (1:200; Invitrogen). Slips were 
mounted using VectaShield (Vector Laboratories), and images were cap-
tured using a microscope (Axio Imager; Carl Zeiss, Inc.) equipped with 
Plan-Apochromat objectives (20  ×   with 0.8 NA or 63  ×   oil with 1.4 NA), a 
charge-coupled device camera (Hamamatsu), and Metamorph software 
(Version 6.3r5; MDS Analytical Technologies). Confocal images were cap-
tured with an NLO Multiphoton (LSM 510; Carl Zeiss, Inc.) on a micro-
scope (Axioskop2 FS; Carl Zeiss, Inc.) equipped with Plan-Neoﬂ  uar 
objectives (40 or 100  ×   oil with 1.3 NA) and a charge-coupled device 
camera. Brightness and contrast were adjusted using Photoshop software 
(Version 8.0; Adobe). 
  To label surface     7* nAChRs, live sensory neurons were incubated 
in     BgTx-488 (1:500; Invitrogen) for 15  –  20 min at 37  °  C. Cells were ﬁ  xed 
and incubated in rabbit anti  –  Alexa 488 (1:250; Invitrogen) overnight at 
4  °  C, followed by secondary antibody incubation. Surface cluster number 
and area were measured along NF-positive processes (  ≥  10   μ  m from soma) 
using Metamorph software. The lengths of axonal processes were mea-
sured by manually tracing NF-positive processes. Control cultures in each 
experiment were used to deﬁ  ne the threshold for measuring clusters at 50% JCB • VOLUME 181 • NUMBER 3 • 2008  520
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  Statistical signiﬁ  cance 
  For normally distributed data, statistical signiﬁ   cance was evaluated by 
ANOVA with a post-hoc Fischer  ’  s PLSD test for multiple comparisons (Stat-
view; Adept Scientiﬁ  c). Non-normally distributed data were analyzed us-
ing nonparametric methods and are presented using box plots. The boxes 
include data points within the middle 50%. The bottom marks the twenty-
ﬁ  fth percentile, the middle line the ﬁ  ftieth percentile, and the top the 
seventy-ﬁ  fth percentile. Vertical lines mark the ﬁ  fth and ninety-ﬁ  fth percentiles 
(see   Devay et al. [1999]   for a detailed description of data presentation). 
Statistical signiﬁ  cance was evaluated by the Kolmogorov-Smirnov test. 
  Online supplemental material 
  In Fig. S1, we show that endocytic recycling of transferrin (A and B) and the 
trafﬁ  cking of presynaptic proteins vGlut1 and synaptophysin (C and D) are 
not impaired in Type III Nrg1 
    /      sensory neurons. Additionally, we show 
that activation of Type III Nrg1 back-signaling does not induce an increase 
in the surface expression of TrkA along axons (E and F). Fig. S2 shows sol-
uble ErbB4-ECD (B4-ECD) bound to Type III Nrg1 puncta along WT axons 
only (A). B4-ECD treatment induces an increase in the axonal surface ex-
pression of     7*nAChRs in a dose-dependent manner (B). Fig. S3 shows that 
Type III Nrg1 back signaling activates Akt in neurons and not nonneuronal 
cells (A). Inhibition of ErbB (B) or TrkA (C) kinase activity does not prevent 
the B4-ECD-induced response. We also show that B4-ECD treatment does 
not activate MAPK in neurons (D). Fig. S4 consists a diagram summarizing 
a mechanism by which Type III Nrg1 back-signaling regulates the levels 
of     7*nAChRs along axons. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.200710037/DC1. 
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